XENE Stock Analysis: Buy, Sell, or Hold?
XENE - Xenon Pharmaceuticals Inc
$54.48
-1.05 (-1.89%)
▼
5d:
-0.84%
30d:
+21.28%
90d:
+20.42%
BUY
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 11, 2026
Smart Money Accumulation
XENE is down 3.3% this week, but smart money is accumulating calls. Top strike: $55 2026-05-15 with 30 OI. Call ratio: 100% View Scanner →
Strength: 6.6/10
Get Alerted When XENE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: XENE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: XENE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: XENE is currently trading at $54.48, which is considered slightly high relative to its 30-day fair value range of $42.54 to $56.50.
Technical Outlook: Technically, XENE is in a uptrend. Immediate support is located at $52.55, while resistance sits at $56.66.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $79.14 (+45.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XENE is in a uptrend. Immediate support is located at $52.55, while resistance sits at $56.66.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $79.14 (+45.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$42.54 -
$56.50
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.8%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 45.3% below Wall St target ($79.14)
Fair Price Analysis
30-Day Fair Range
$42.54 -
$56.50
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$52.55
Resistance Level
$56.66
Current Trend
Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.49
Wall Street Target
$79.14
(+45.3%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: March 30, 2026 7:03 AM ET
Data refreshes hourly during market hours. Next update: 8:03 AM
Data refreshes hourly during market hours. Next update: 8:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XENE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Andrea Difabio
SELL
1342 shares
2026-03-13
Christopher John Kenney
SELL
1410 shares
2026-03-13
Ian Mortimer
SELL
7308 shares
2026-03-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 56 HOLD |
Advanced XENE Option Strategies
Professional options setups generated by AI based on today's XENE price and gamma walls.